Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shrink liver tumors in hard-to-treat colorectal cancer

NCT ID NCT06356584

Recruiting now Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will be randomly assigned to receive the drug combo with or without radiotherapy. The goal is to see if the triple therapy improves how long the cancer stays under control and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER IMMUNOTHERAPY LIVER METASTASIS RADIOTHERAPY TARGETED THERAPY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jinbo Yue

    RECRUITING

    Jinan, Shandong, 250000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••